...&D Systems adds two new Stem Cell Antibody Panels ...uman Embryonic Stem Cell Marker Antibody Panel (Ca...kaline phosphatase, Nanog, Oct-3/4, SSEA-1 and SSE... Panel Plus (Catalog # SC009) contains antibodies ...
Anti-Epstein-Barr Virus (EBV) (EBNA-1) Polyclonal Antibody, Biotin Conjugated from ViroStat Inc.
Rabbit Anti-ECE-1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rat Anti-Mouse HAI-1 Ectodomain Monoclonal Antibody, Unconjugated, Clone 199732 from R&D Systems
Biology Products:(Date:11/19/2009)...ire/ -- Dr. Mate Hidvegi, inventor of Avemar ferme...se issued on November 17 by Biropharma Kft, discre...self-serving statements about its U.S. competitor ...om his office in Budapest, Hungary: ,, "The Bi...ply to AveULTRA, www.aveultra.com , is misleadi...
(Date:11/19/2009)...rstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), anno...to its shareholders, discussing the Company,s acqu...uticals Holdings, Inc. (CHBP), an integrated bio-p...ic of China. The merger gives NeoStem a controllin...td., CHBP,s primary operating subsidiary and a pro...
(Date:11/19/2009)...ss., Nov. 19 Arlington Medical Res...leading driver of antibiotic selection in nosocomi...against gram-positive and gram-negative pathogens....socomial pneumonia, surveyed European physicians r...vide appropriate coverage against common pathogens...
(Date:11/19/2009)... Aegera Therapeutics Inc. announced today the dosi...tudy of AEG35156, a targeted antisense therapeutic...dications. ,, The study, entitled "An Open-Labe...or of Apoptosis (XIAP) Antisense AEG35156 Given in...cin in AML Following Failure of a Single Standard ...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2